CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
disruption in lymphocytes was only approximately 5%, which indicates the need for further research into this approach. (Funded by the Beijing Municipal Science and Technology Commission and others; ClinicalTrials.gov number, NCT03164135.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Subsequent experiments showed that p53 inactivation can be controlled or avoided through protocol optimization 47,107 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [107]
Citations
Cites
1 retracted
CCR5-∆32 is deleterious in the homozygous state in humans
Wei, X., & Nielsen, R. (2019) · Nature Medicine · doi:10.1038/s41591-019-0459-6 · Cited by 75
RetractedIdentification of a major co-receptor for primary isolates of HIV-1
Deng, H., Liu, R., Ellmeier, W., Choe, S., Unutmaz, D., Burkhart, M., Marzio, P. D., Marmon, S., Sutton, R. E., Hill, C. M., et al. (1996) · Nature · doi:10.1038/381661a0 · Cited by 3,641
Self-citationSamson, M., Libert, F., Doranz, B. J., Rucker, J., Liesnard, C., Farber, C.-M., Saragosti, S., Lapouméroulie, C., Cognaux, J., Forceille, C., et al. (1996) · Nature · doi:10.1038/382722a0 · Cited by 2,886
A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867
Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation
Hütter, G., Nowak, D., Mossner, M., Ganepola, S., Müßig, A., Allers, K., Schneider, T., Hofmann, J., Kücherer, C., Blau, O., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0802905 · Cited by 1,837
Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV
Tebas, P., Stein, D., Tang, W. W., Frank, I., Wang, S. Q., Lee, G., Spratt, S. K., Surosky, R. T., Giedlin, M. A., Nichol, G., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300662 · Cited by 1,357
CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes
Komor, A. C., Badran, A. H., & Liu, D. R. (2017) · Cell · doi:10.1016/j.cell.2016.10.044 · Cited by 1,013
Gene Therapy for Immunodeficiency Due to Adenosine Deaminase Deficiency
Aiuti, A., Cattaneo, F., Galimberti, S., Benninghoff, U., Cassani, B., Callegaro, L., Scaramuzza, S., Andolfi, G., Mirolo, M., Brigida, I., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805817 · Cited by 1,007
Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases
Perez, E. E., Wang, J., Miller, J. C., Jouvenot, Y., Kim, K. A., Liu, O., Wang, N., Lee, G., Bartsevich, V. V., Lee, Y.-L., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1410 · Cited by 999
Self-citationCRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells
Dever, D. P., Bak, R. O., Reinisch, A., Camarena, J., Washington, G., Nicolas, C. E., Pavel-Dinu, M., Saxena, N., Wilkens, A. B., Mantri, S., et al. (2016) · Nature · doi:10.1038/nature20134 · Cited by 864
Cited by
Items 201–300 of 468
Therapeutic applications of CRISPR-Cas9 gene editing
Bharti, A., & Mudge, J. (2025) · Frontiers in Genome Editing · doi:10.3389/fgeed.2025.1724291 · Cited by 17
Banda, A., Impomeni, O., Singh, A., Baloch, A. R., Hu, W., & Jaijyan, D. K. (2024) · Vaccines · doi:10.3390/vaccines12060636 · Cited by 18
“CRISPR was used to disrupt the CCR5 gene in hematopoietic stem cells and progenitor cells obtained from patients to treat HIV-1 infection [268].”
MethodEmerging Gene-editing nano-therapeutics for Cancer
Nujoom, N., Koyakutty, M., Biswas, L., Rajkumar, T., & Nair, S. V. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e39323 · Cited by 20
From Berlin to London: HIV-1 Reservoir Reduction Following Stem Cell Transplantation
Prator, C. A., Donatelli, J. L., & Henrich, T. J. (2020) · Current HIV/AIDS Reports · doi:10.1007/s11904-020-00505-2 · Cited by 16
Christopher, A. C., Venkatesan, V., Karuppusamy, K. V., Srinivasan, S., Babu, P., Azhagiri, M. K. K., Chambayil, K., Bagchi, A., Rajendiran, V., Ravi, N. S., et al. (2022) · Human Gene Therapy · doi:10.1089/hum.2021.089 · Cited by 16
“1 The promising progress of lentiviral gene modification studies for b - -hemoglobinopathies, primary immunodeficiency disorders, and lysosomal storage diseases 2–5 as well as gene-editing studies for b -hemoglobinopathies and HIV 6,7 highlight the therapeutic benefits of autologous HSPC gene therapy.”
Emerging trends in gene and cell therapy: CRISPR in DNA editing and beyond
Ji, R., Chen, Q., & Zhang, Y. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102459 · Cited by 19
“140 These trials showed stable engraftment of edited cells, but the low editing efficiency limited clinical efficacy in eradicating HIV reservoirs.”
Self-citationAntiretrovirals to CCR5 CRISPR/Cas9 gene editing - A paradigm shift chasing an HIV cure
Khan, A., Nandagopal, P., & Lawson, B. R. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109741 · Cited by 18
Advances in engineered T cell immunotherapy for autoimmune and other non-oncological diseases
Huang, Q., Zhu, X., & Zhang, Y. (2025) · Biomarker Research · doi:10.1186/s40364-025-00736-8 · Cited by 16
Self-citationFeist, W. N., Luna, S. E., Ben-Efraim, K., Interrante, M. V. F., Amorin, A., Johnston, N. M., Bruun, T. U. J., Utz, A., Ghanim, H. Y., Lesch, B. J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58371-8 · Cited by 16
“One recent trial demonstrated the feasibility of autologous transplantation of cells genetically modi fi ed for CCR5 KO in a patient with HIV-1 42 .”
Schwarze, L. I., Sonntag, T., Wild, S., Schmitz, S., Uhde, A., & Fehse, B. (2021) · Gene Therapy · doi:10.1038/s41434-021-00259-5 · Cited by 15
“These included blockade of HIV entry via CCR5 knockout using different types of designer nucleases, namely ZFN [18], TAL effector nucleases [TALEN] [19] and CRISPR/Cas9 [20], but also HIV provirus excision using designer recombinases [21] as well as nucleases [22].”
BackgroundBauss, J. M., Morris, M., Shankar, R., Olivero, R. M., Buck, L., Stenger, C. L., Hinds, D., Mills, J., Eby, A., Zagorski, J. W., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.790041 · Cited by 15
“While the potential for CRISPR editing of CCR5 to create HIV resistance is intriguing (28), a more complex understanding of CCR5 biology is critical.”
BackgroundGrand Challenges on HIV/AIDS in China – The 5th Symposium, Yunnan 2024
Chen, Z., Xu, J., Jin, X., Wang, J., Huang, J., Zhang, H., Chen, L., Deng, K., Cai, W., Li, L., et al. (2025) · Emerging Microbes & Infections · doi:10.1080/22221751.2025.2492208 · Cited by 17
“To address this, CRISPR-edited CCR5-ablated haematopoietic stem and progenitor cells (HSPCs) were tested in a Chinese patient with HIV-1 infection and acute lymphoblastic leukaemia [85].”
Self-citationNew hope and promise with CRISPR-Cas9 technology for the treatment of HIV
Hassan, H. M., Zubair, A., Helal, M. H., Almagharbeh, W. T., & Elmagzoub, R. M. (2025) · Functional & Integrative Genomics · doi:10.1007/s10142-025-01613-1 · Cited by 20
Transcription‐independent functions of p53 in DNA repair pathway selection
Wang, Y., & Sheetz, M. P. (2022) · BioEssays · doi:10.1002/bies.202200122 · Cited by 15
RETRACTED ARTICLE: Revolutionizing Lung Cancer Treatment: Innovative CRISPR-Cas9 Delivery Strategies
Singh, D. (2024) · AAPS PharmSciTech · doi:10.1208/s12249-024-02834-6 · Cited by 15
RetractedCurrent trends in gene therapy to treat inherited disorders of the brain
Matuszek, Ż., Brown, B. L., Yrigollen, C. M., Keiser, M. S., & Davidson, B. L. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.057 · Cited by 14
CCR5 gene editing and HIV immunotherapy: current understandings, challenges, and future directions
Wang, J., Liu, J., & Xun, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1590690 · Cited by 14
“Lessons learned from the fi rst-in-human CRISPR-HSPC transplantation trial, which reported no serious adverse events during 19-month follow-up (43), can inform early ef fi cacy assessments and data collection for future trials.”
Self-citationDesigner Nucleases: Gene-Editing Therapies using CCR5 as an Emerging Target in HIV
Almeida, M. J., & Matos, A. M. (2019) · Current HIV Research · doi:10.2174/1570162x17666191025112918 · Cited by 13
A CRISPR view of hematopoietic stem cells: Moving innovative bioengineering into the clinic
Worthington, A. K., & Forsberg, E. C. (2022) · American Journal of Hematology · doi:10.1002/ajh.26588 · Cited by 17
Precise measurement of CRISPR genome editing outcomes through single-cell DNA sequencing
Kalter, N., Gulati, S., Rosenberg, M., Ayaz, Q., Nguyen, J., Wang, S., Schroeder, B., Li, C.-Y., & Hendel, A. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101449 · Cited by 18
Self-citationCRISPR/Cas9 for achieving postintervention HIV control
Moso, M. A., Roche, M., Cevaal, P. M., & Lewin, S. R. (2025) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000963 · Cited by 13
“…achieved is a significant advance over the previously described studies using zinc finger nucleases [14,15] and initial CRISPR/Cas9 studies [16,20], and could be a result of the use of optimized gRNA target sites Engraftment of CCR5-edited HSPCs was stable in vivo and cells were able to…”
Lee, P., Keller, M. D., Hanley, P. J., & Bollard, C. M. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00298 · Cited by 15
Generation of HIV-resistant cells with a single-domain antibody: implications for HIV-1 gene therapy
Jin, H., Tang, X., Li, L., Chen, Y., Zhu, Y., Chong, H., & He, Y. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00627-y · Cited by 13
Lin, D., Scheller, S. H., Robinson, M. M., Izadpanah, R., Alt, E., & Braun, S. E. (2021) · The CRISPR Journal · doi:10.1089/crispr.2020.0019 · Cited by 13
Nucleases in gene-editing technologies: past and prologue
Li, D., Li, L.-Q., & Liu, J. (2023) · National Science Open · doi:10.1360/nso/20220067 · Cited by 13
“A clinical trial (NCT03164135) in which transplantation of CRISPR-edited CCR5-ablated hematopoietic stem and progenitor cells (HSPCs) was used to treat HIV infection is also reported [176].”
BackgroundChoi, I. Y., Lim, H., Huynh, A., Schofield, J. H., Cho, H. J., Lee, H., Andersen, P., Shin, J. H., Heo, W. D., Hyun, S., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120222 · Cited by 13
Wang, L., Jiang, J., Li, X., Li, K., He, R., Li, J., Duan, L., Luo, W., Hu, Z. M., & Luo, D. (2020) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmaa123 · Cited by 12
Self-citationSmall nucleic acids and the path to the clinic for anti-CRISPR
Barkau, C. L., O’Reilly, D., Eddington, S. B., Damha, M. J., & Gagnon, K. T. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114492 · Cited by 12
Prime editing: A potential treatment option for β‐thalassemia
Arif, T., Farooq, A., Ahmad, F. J., Akhtar, M., & Choudhery, M. S. (2022) · Cell Biology International · doi:10.1002/cbin.11972 · Cited by 14
Major, L., McClements, M. E., & MacLaren, R. E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087603 · Cited by 12
“Limitations Nonetheless, some studies have not achieved sufficient levels of correction via the NHEJ pathway for significant phenotypic results: 5% editing of stem cells in a patient with HIV and ALL was not enough to mitigate HIV infection [27].”
BackgroundPark, J. D., Shin, H. E., An, Y. S., Jang, H. J., Park, J., Kim, S.-N., Park, C. G., & Park, W. (2025) · Annals of Laboratory Medicine · doi:10.3343/alm.2024.0380 · Cited by 11
Deep Thought on the HIV Cured Cases: Where Have We Been and What Lies Ahead?
Xiao, Q., He, S., Wang, C., Zhou, Y., Zeng, C., Li, J., Liu, T., Li, T., Quan, X., Wang, L., et al. (2025) · Biomolecules · doi:10.3390/biom15030378 · Cited by 11
“It is feasible to develop new treatment methods based on the elements that might have led to HIV elimination in the cured cases [21].”
Self-citationBiomedical Interventions for HIV Prevention and Control: Beyond Vaccination
Liao, Y., Wen, Z., Shi, M., Zou, H., & Sun, C. (2025) · Viruses · doi:10.3390/v17060756 · Cited by 13
“However, the percentage of CCR5-deficient lymphocytes following treatment remains relatively low (approximately 5%), which results in limited efficacy in controlling HIV infection, underscoring the need for further research to refine this approach [173].”
Targeted and epigenetic therapies for acute myeloid leukemia treatment
Shokoohi, M., Ghaderi, M., Mokarami, M., Arian, H., Mohammadnabi, S., & Farokhi, A. (2025) · Discover Oncology · doi:10.1007/s12672-025-03534-8 · Cited by 13
“CRISPR/Cas9 gene editing application in AML is also undergoing assessment for safety and effectiveness in multiple early-phase clinical trials [110, 111].”
Yu, S., Ou, Y., Xiao, H., Li, J., Adah, D., Liu, S., Zhao, S., Li, Q., Yao, Y., & Chen, X. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.03.004 · Cited by 11
“Recently, Xu et al.(13) transplanted the CRISPR-mediated CCR5-”
BackgroundCRISPR/Cas-Based Gene Editing Strategies for DOCK8 Immunodeficiency Syndrome
Ravendran, S., Hernández, S. S., König, S., & Bak, R. O. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.793010 · Cited by 12
Ponta, S., Bonato, A., Neidenbach, P., Bruhin, V. F., Laurent, A. E., Applegate, L. A., Zenobi‐Wong, M., & Barreto, G. (2024) · Arthritis Research & Therapy · doi:10.1186/s13075-024-03294-w · Cited by 11
“CRISPR-Cas9 RNP strategies are effectively already employed for a wide variety of other diseases, mainly for cancer immunotherapy [66], hematologic disorders [67] and immune system disorders [68].”
BackgroundThe CRISPR/Cas system as an antimicrobial resistance strategy in aquatic ecosystems
Gupta, S. S., Muneeb, K. H., Sones, C. L., Zhang, X., & Sivaraman, G. K. (2024) · Functional & Integrative Genomics · doi:10.1007/s10142-024-01362-7 · Cited by 13
“Currently, CRISPR technology is being used extensively to edit stem cells in patients with HIV-related and acute lymphocytic leukemia-reversed disease (Xu et al. 2019).”
Regenerative rehabilitation: a novel multidisciplinary field to maximize patient outcomes
Deng, C., Aldali, F., Luo, H., & Chen, H. (2024) · Medical Review · doi:10.1515/mr-2023-0060 · Cited by 13
Self-citationThe origin of unwanted editing byproducts in gene editing
Yin, J., & Hu, J. (2022) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2022056 · Cited by 12
Karuppusamy, K. V., Babu, P., & Thangavel, S. (2021) · Stem Cell Reviews and Reports · doi:10.1007/s12015-021-10145-7 · Cited by 14
Chen, Y., Jin, H., Tang, X., Li, L., Geng, X., Zhu, Y., Chong, H., & He, Y. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.2011616 · Cited by 11
Zubair, A., Ali, M., Ahmad, F., & Althobaiti, S. A. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10993-3 · Cited by 11
“No adverse events were observed during the first three months, and no serious events occurred [85].”
Pfenninger, P., Yerly, L., & Abe, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.777113 · Cited by 12
Genome Editing in Translational Medicine: An Inventory
Dobner, J., Ramachandran, H., & Rossi, A. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2708241 · Cited by 11
“In another published case report, the authors described CRISPR/Cas-based treatment of a patient with acute lympathic leukemia (ALL) and a coexisting HIV infection [95].”
BackgroundInfluentialSchnarr, A., & Mertz, M. (2022) · Science and Engineering Ethics · doi:10.1007/s11948-022-00418-w · Cited by 11
Selim, H. M. R. M., Gomaa, F. A. M., Alshahrani, M. Y., & Aboshanab, K. M. (2024) · Infectious Diseases & Immunity · doi:10.1097/id9.0000000000000149 · Cited by 12
The Use of Genomics to Drive Kidney Disease Drug Discovery and Development
Reilly, D. F., & Breyer, M. D. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11070919 · Cited by 10
CRISPR in medicine: applications and challenges
Sun, J., Hu, H., Cheng, Y., & Lu, X. (2020) · Briefings in Functional Genomics · doi:10.1093/bfgp/elaa011 · Cited by 10
Self-citationTargeting and Understanding HIV Latency: The CRISPR System against the Provirus
Magro, G., Calistri, A., & Parolin, C. (2021) · Pathogens · doi:10.3390/pathogens10101257 · Cited by 10
“Based on these findings, gene editing technologies, such as zinc-finger nucleases (ZFN) [21], transcription activator-like effector nucleases (TALEN) [22], and more recently, CRISPR-Cas [23], have been developed to edit ex vivo the CCR5 gene, and make the cells resistant to infection, an approach that has also been te…”
BackgroundPuerta-Guardo, H. N., & Manrique-Saide, P. C. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.98177 · Cited by 12
D'Souza, S. S., Kumar, A., Weinfurter, J. T., Park, M. A., Maufort, J. P., Tao, L., Kang, H., Dettle, S. T., Golos, T. G., Thomson, J. A., et al. (2022) · Stem Cell Reports · doi:10.1016/j.stemcr.2022.03.003 · Cited by 10
“Gene editing to inactivate theCCR5 gene using nucleases has shown promising results toward developing a functional HIV cure (Mock et al., 2015; Mussolino et al., 2014; Tebas et al., 2014; Xu et al., 2019).”
Genome Editing Technologies as Cellular Defense Against Viral Pathogens
Zhang, Y., & Li, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.716344 · Cited by 15
Self-citationEmerging Use of CRISPR Technology — Chasing the Elusive HIV Cure
June, C. H. (2019) · New England Journal of Medicine · doi:10.1056/nejme1910754 · Cited by 10
A systematic review of gene editing clinical trialsPreprint
Eshka, S. F. A., Bahador, M., Gordan, M. M., Karbasi, S., Tabar, Z. M., & Basiri, M. (2022) · medRxiv · doi:10.1101/2022.11.24.22282599 · Cited by 11
“No results have been published from this trial yet, and studies are still ongoing (Xu et al., 2019).”
BackgroundTarget product profile for cell-based and gene-based therapies to achieve a cure for HIV
Lewin, S. R., Bansbach, C., Kemps, D., Mathae, L., Das, K. T., McCune, J. M., Deeks, S. G., & Ndung'u, T. (2025) · The Lancet HIV · doi:10.1016/s2352-3018(24)00277-7 · Cited by 9
Host-directed approaches in the pursuit of a cure for HIV
Shepherd, R. A., Tanaka, K., King, H. A. D., Schou, M. D., Williams, O. H. L., Kim, Y., Roche, M., & Lewin, S. R. (2025) · Antiviral Research · doi:10.1016/j.antiviral.2025.106216 · Cited by 12
“In a single recipient who received CRISPR/Cas9 CCR5 modified cells as part of treatment for acute lymphocytic leukemia the modified cells were long lived (19 months), but only 5 % of circulating lymphocytes were successfully modified (Xu et al., 2019).”
Głów, D., Meyer, S., Roldán, I. G., Akingunsade, L., Riecken, K., & Fehse, B. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.07.004 · Cited by 11
“In fact, prime editing was shown to mediate targeted insertions, deletions, all 12 possible base-to-base conversions, and combinations thereof in human cells without requiring doublestrand breaks (DSBs) or donor DNA templates.8 Altogether, genome editing and particularly CRISPR/Cas9 have become a broadly used tool in…”
BackgroundThe discovery and development of RNA-based therapies for treatment of HIV-1 infection
Chen, M. J., Gatignol, A., & Scarborough, R. J. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2117296 · Cited by 10
“using technologies such as zinc finger nucleases [193] and clustered regularly interspaced palindromic repeats associated nucleases [194].”
MethodWichmann, M., Maire, C. L., Nuppenau, N., Habiballa, M., Uhde, A., Kolbe, K., Schröder, T., Lamszus, K., Fehse, B., & Głów, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411399 · Cited by 10
Immune dysregulation syndrome with de novo CTLA4 germline mutation responsive to abatacept therapy
Ureshino, H., Koarada, S., Kamachi, K., Yoshimura, M., Yokoo, M., Kubota, Y., Ando, T., Ichinohe, T., Morio, T., & Kimura, S. H. (2020) · International Journal of Hematology · doi:10.1007/s12185-020-02834-9 · Cited by 9
Wang, C., Sun, S., Teckman, J. H., & Balch, W. E. (2020) · Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation · doi:10.15326/jcopdf.7.3.2019.0167 · Cited by 9
Protière, C., Fiorentino, M., Sow, A., Préau, M., Mora, M., Fressard, L., Meyer, L., Lelièvre, J., Lambotte, O., Spire, B., et al. (2020) · AIDS · doi:10.1097/qad.0000000000002530 · Cited by 9
An overview of applications of CRISPR-Cas technologies in biomedical engineering
Jamehdor, S., Zaboli, K. A., Naserian, S., Thekkiniath, J., Omidy, H. A., Teimoori, A., Johari, B., Taromchi, A. H., Sasano, Y., & Kaboli, S. (2020) · Folia Histochemica et Cytobiologica · doi:10.5603/fhc.a2020.0023 · Cited by 9
“This strategy has been implemented for treating HIV-1 infection and acute lymphoblastic leukemia [85].”
MethodPache, M. M., Pangavhane, R. R., Nikam, S. V., Rode, R. B., & Darekar, A. B. (2025) · Research Journal of Science and Technology · doi:10.52711/2231-5713.2025.00045 · Cited by 9
Chakraborty, C., Bhattacharya, M., Das, A., Agoramoorthy, G., & Lee, S.-S. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102859 · Cited by 12
“69 The study was registered for a clinical trial (clinical trial id: NCT03164135).”
Precision Genome Editing Techniques in Gene Therapy: Current State and Future Prospects
Singh, K., Bhushan, B., Kumar, S., Singh, S., Macadangdang, R. R., Pandey, E., Varma, A. K., & Kumar, S. (2024) · Current Gene Therapy · doi:10.2174/0115665232279528240115075352 · Cited by 11
Li, S., Zhang, L., Li, M., Huang, J., Cui, B., Jia, J., Guo, Z., Ma, K., & Cui, C. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.02.025 · Cited by 8
CRISPR/Cas and Hepatitis B Therapy: Technological Advances and Practical Barriers
Kostyushev, D. S., Kostyusheva, A. P., Ponomareva, N. I., Brezgin, S. A., & Chulanov, V. (2021) · Nucleic Acid Therapeutics · doi:10.1089/nat.2021.0075 · Cited by 9
“Efficacy of CRISPR/Cas9 as anti-HIV therapy in humans has also been described [110].”
One arrow for two targets: potential co-treatment regimens for lymphoma and HIV
Chen, X., Jia, L., Zhang, X., Zhang, T., & Zhang, Y. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.100965 · Cited by 8
Self-citationRGEN Editing of RNA and DNA: The Long and Winding Road from Catalytic RNAs to CRISPR to the Clinic
Sullenger, B. A. (2020) · Cell · doi:10.1016/j.cell.2020.04.050 · Cited by 8
Xu, Y., Peng, X., Zheng, Y., Jin, C., Lu, X., Han, D., Fu, H., Chen, C., & Wu, N. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.629153 · Cited by 10
Self-citationThe path to biotechnological singularity: Current breakthroughs and outlook
Wen, Z., Yang, D., Yang, Y., Hu, J., Parviainen, A., Chen, X., Li, Q., VanDeusen, E. A., Ma, J., & Tay, F. R. (2025) · Biotechnology Advances · doi:10.1016/j.biotechadv.2025.108667 · Cited by 8
CRISPR-Cas technologies: Emerging tools from research to clinical application
Hyeon, H., Hwang, S., Luo, Y., Shin, E., Yeom, J., Kim, H., Ryu, M., & Lee, K. (2025) · The Journal of Microbiology · doi:10.71150/jm.2504012 · Cited by 8
“However, the proportion of modified lymphocytes was low (5%), prompting the exploration of advanced strategies to improve the efficiency of gene modification (Xu et al., 2019).”
Wu, X., Jin, S., Pan, Y., Zhen, W., Yu, S., Zhang, Y., Xu, F. Y., Wang, R., Wu, M., Sun, W., et al. (2026) · Stem Cell Research & Therapy · doi:10.1186/s13287-026-04997-4 · Cited by 7
Self-citationCXCR4 Is a Potential Target for Anti-HIV Gene Therapy
Prokopovich, A. K., Litvinova, I. S., Zubkova, A. E., & Yudkin, D. V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021187 · Cited by 7
“…NCT02337985, NCT01961063, NCT01153646, NCT00569985), zinc-finger nucleases (ZFNs) for CCR5 knockout (NCT02500849, NCT02225665, NCT02388594, NCT01044654, NCT01252641, NCT00842634, NCT03666871, NCT03617198), and CRISPR-Cas9 for CCR5 knockout (NCT03164135, NCT05144386, NCT05143307) [17–19].”
Understanding on CRISPR/Cas9 mediated cutting-edge approaches for cancer therapeutics
Bhattacharjee, R., Roy, L. D., & Choudhury, A. (2022) · Discover Oncology · doi:10.1007/s12672-022-00509-x · Cited by 7
“Interestingly, they study did not find any off-target effects of the CRISPR edits in the patient [79].”
BackgroundGet ready for the CRISPR/Cas system: A beginner's guide to the engineering and design of guide RNAs
Ma, S., Lv, J., Feng, Z., Rong, Z., & Lin, Y. (2021) · The Journal of Gene Medicine · doi:10.1002/jgm.3377 · Cited by 8
“to mutate gene CCR5 for the first patient to receive cells therapy to cure human immunodeficiency virus (HIV).(117) The results showed no significant side effects, suggesting that the treatment can be safely used in the clinic.”
BackgroundTargeted insertion of large genetic payloads using cas directed LINE-1 reverse transcriptase
Manoj, F., Tai, L. W., Wang, K. S. M., & Kuhlman, T. E. (2021) · Scientific Reports · doi:10.1038/s41598-021-03130-0 · Cited by 7
Clinical Pharmacology and Translational Considerations in the Development of CRISPR‐Based Therapies
Abdelhady, A. M., Phillips, J. A., Xu, Y., & Stroh, M. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3000 · Cited by 11
“Owing to a relatively low percentage of CCR5 disruption, this investigation was viewed as a proof- of- principle more so than illustration of a fully curative intervention for HIV.66”
Precision medicine in the era of CRISPR-Cas9: evidence from Bosnia and Herzegovina
Semiz, S., & Aka, P. C. (2019) · Humanities and Social Sciences Communications · doi:10.1057/s41599-019-0346-2 · Cited by 7
Ye, L., Wang, J., Teque, F., Xie, F., Tan, Y., Kan, Y. W., & Levy, J. A. (2020) · AIDS · doi:10.1097/qad.0000000000002535 · Cited by 8
“Recently, allogeneic hematopoietic stem and progenitor cells were edited with CRISPR to delete CCR5 and transplanted into one HIV patient on ART with acute lymphoblastic leukemia [52].”
BackgroundSelf-citationProtière, C., Fressard, L., Mora, M., Meyer, L., Préau, M., Suzan, M., Lelièvre, J., Lambotte, O., Spire, B., & the APSEC Study Group (2020) · Vaccines · doi:10.3390/vaccines8020334 · Cited by 7
Pathways Toward a Functional HIV-1 Cure: Balancing Promise and Perils of CRISPR Therapy
Herskovitz, J., Hasan, M., Patel, M., Kevadiya, B. D., & Gendelman, H. E. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1871-4_27 · Cited by 12
Kantor, B., Duke, L. C., & Bhide, P. G. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102786 · Cited by 8
Phenotypic and Immunometabolic Aspects on Stem Cell Memory and Resident Memory CD8+ T Cells
Manna, M. P. L., Azgomi, M. S., Tamburini, B., Badami, G. D., Mohammadnezhad, L., Dieli, F., & Caccamo, N. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.884148 · Cited by 9
Recent advances in CRISPR/Cas9-assisted gene therapy
Srivastava, A., Chauhan, S., & Ahuja, V. (2023) · Karbala International Journal of Modern Science · doi:10.33640/2405-609x.3330 · Cited by 6
Integrating CRISPR/Cas technology with clinical trials: Principles, progress and challenges
Yang, P., Khoshandam, M., Bhia, I., Raji, S., Soltaninejad, H., Hosseinkhani, S., Sani, M., Hamidieh, A. A., & Sheykhhasan, M. (2025) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2025.101068 · Cited by 10
“Furthermore, a 27-year-old male diagnosed with HIV-1 and severe lymphoblastic leukemia received successful and long-lasting transplantation of CRISPR-modified HSPCs [ 115 ].”
Gene therapy in China: past, present, and future
Zhang, L. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00356-8 · Cited by 6
Combined application of CRISPR-Cas and stem cells for clinical and basic research
Yan, M., & Li, J. (2020) · Cell Regeneration · doi:10.1186/s13619-020-00062-4 · Cited by 9
Implications of Chromatin Modifier Mutations in Epigenetic Regulation of Bladder Cancer
Akman, B., & Erkek, S. (2022) · Exon Publications eBooks · doi:10.36255/exon-publications-urologic-cancers-bladder-cancer-epigenetics · Cited by 7
Characteristics of CD8 + Stem Cell-Like Memory T Cell Subset in Chronic Hepatitis C Virus Infection
Lu, X., Song, B., Weng, W., Su, B., Wu, H., Cheung, A. K. L., Zhang, T., & Gao, Y. (2022) · Viral Immunology · doi:10.1089/vim.2022.0079 · Cited by 6
Self-citationApplications of CRISPR/Cas9 in the research of malignant musculoskeletal tumors
Liu, W., Wang, S., Lin, B., Zhang, W., & Ji, G. (2021) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-021-04020-2 · Cited by 7
From Descriptive to Functional Genomics of Leukemias Focusing on Genome Engineering Techniques
Balla, B., Tripon, F., & Bănescu, C. V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810065 · Cited by 6
Phages, anti-CRISPR proteins, and drug-resistant bacteria: what do we know about this triad?
Ceballos-Garzón, A., Muñoz, A. B., Plata, J. D., Sánchez-Quitian, Z. A., & Ramos-Vivas, J. (2022) · Pathogens and Disease · doi:10.1093/femspd/ftac039 · Cited by 9
A first step toward in vivo gene editing in patients
Büning, H., & Schambach, A. (2021) · Nature Medicine · doi:10.1038/s41591-021-01476-6 · Cited by 6
Recent development in CRISPR-Cas systems for cardiac disease
Munshi, I. D., Acharya, M., Mukherjee, S., & Mani, I. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.08.004 · Cited by 6
Next-generation gene therapy for infectious disease: Advances, challenges, and future directions
Fattahi, M., Pirbadami, F., Motallebirad, T., Beheshti, Z., & Azadi, D. (2026) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2026.103164 · Cited by 5
Improving the efficiency of high-fidelity Cas9 by enhancing PAM-distal interactions
Zheng, R., Lu, Z., Wei, R., Shin, Y.-C., Du, J., Zhang, Q., Li, J., Wang, X., Wei, Y., Liu, B., et al. (2026) · Nature Structural & Molecular Biology · doi:10.1038/s41594-026-01753-3 · Cited by 5
Self-citationCRISPR–Cas9 Therapeutics in Early Clinical Development: Delivery and Molecular Diagnostics
Rutkowska, A., Strózik, T., Wasiak, T., Ciunowicz, D., Kapelan, N., Szczepaniak, N., Sosnowski, J., Goślińska, W., Bartkowiak, J., Budny-Lewandowska, A., et al. (2026) · Cells · doi:10.3390/cells15070644 · Cited by 5
Metadata
- Authors
- Xu, L., Wang, J., Liu, Y., Xie, L., Su, B., Mou, D., Wang, L., Liu, T., Wang, X., Zhang, B., Zhao, L., Hu, L., Ning, H., Zhang, Y., Deng, K., Liu, L., Lu, X., Zhang, T., Xu, J., Li, C., Wu, H., Deng, H., & Chen, H.
- Affiliations
- Peking University (CN)
- Capital Medical University (CN)
- Sun Yat-sen University (CN)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-09-26
- Volume
- 381
- Issue
- 13
- Pages
- 1240-1247
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2972390440
- Cited by
- 454
- References
- 27
- Citations by year
- 2026: 34 · 2025: 52 · 2024: 57 · 2023: 45 · 2022: 77 · 2021: 87 · 2020: 89 · 2019: 13
- FWCI
- 21.99
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Key Research and Development Program of China (2017YFA0103000)
- Beijing Municipal Science and Technology Commission (D171100000517004)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- CRISPR gene editing, hematopoietic stem cells, HIV, acute lymphoblastic leukemia, gene therapy
- MeSH terms
- Gene Editing, Adult, Blood Cell Count, Hematopoietic Stem Cells, Humans, Male, HIV-1, HIV Infections, Hematopoietic Stem Cell Transplantation, CD4 Lymphocyte Count, Viral Load, Receptors, CCR5, Anti-Retroviral Agents, Precursor Cell Lymphoblastic Leukemia-Lymphoma, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.